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Meaghan McAllister13 and Judith Katzenellenbogen14

Abstract
Background: Aboriginal Australians are known to suffer high levels of acquired brain injury (stroke and traumatic
brain injury) yet experience significant barriers in accessing rehabilitation services. The aim of the Healing Right Way
trial is to evaluate a culturally secure intervention for Aboriginal people with newly acquired brain injury to improve
their rehabilitation experience and quality of life. Following publication of the trial protocol, this paper outlines the
statistical analysis plan prior to locking the database.
Methods: The trial involves a stepped wedge design with four steps over 3 years. Participants were 108 adult Aboriginal Australians admitted to one of eight hospitals (four rural, four urban) in Western Australia within 6 weeks of
onset of a new stroke or traumatic brain injury who consented to follow-up for 26 weeks. All hospital sites started in
a control phase, with the intervention assigned to pairs of sites (one metropolitan, one rural) every 26 weeks until all
sites received the intervention. The two-component intervention involves training in culturally safe care for hospital
sites and enhanced support provided to participants by Aboriginal Brain Injury Coordinators during their hospital stay
and after discharge. The primary outcome is quality of life as measured by the Euro QOL–5D-3L VAS. A mixed effects
linear regression model will be used to assess the between-group difference at 26 weeks post-injury. The model will
control for injury type and severity, age at recruitment and time since commencement of the trial, as fixed effects.
Recruitment site and participant will be included as random effects. Secondary outcomes include measurements of
function, independence, anxiety and depression, carer strain, allied health occasions of service received and hospital
compliance with minimum processes of care based on clinical guidelines and best practice models of care.
Discussion: The trial will provide the first data surrounding the effectiveness of an intervention package for Aboriginal people with brain injury and inform future planning of rehabilitation services for this population. The statistical
analysis plan outlines the analyses to be undertaken.
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Background
Brain injury resulting from both stroke and traumatic
injury can have significant ongoing effects on survivors in
terms of affecting their sense of self, social relationships,
mental health and community participation including
employment prospects [1, 2]. Family members’/carers’
quality of life can also be affected as their lives change
when supporting the person with the brain injury [3]. For
Aboriginal Australians, as for other Indigenous populations, stroke occurs at a higher rate than for their nonIndigenous counterparts, and at a relatively younger age,
reflecting the high prevalence of comorbidities such as
diabetes and chronic cardiovascular conditions [4–9].
Traumatic brain injury (TBI) is also known to occur at
a higher rate [10, 11]. Previous research has highlighted
mismatches between community needs and services currently offered to Aboriginal people with brain injury and
their families/community [12–14]. This has resulted in
limited ongoing engagement between Aboriginal people
with brain injury and hospital-based rehabilitation services, with particular challenges for (although not limited to) those living in rural and remote areas. Aboriginal
people with brain injury have highlighted the need for (i)
services that respect and incorporate cultural protocols
and values, (ii) culturally secure assessment and treatment tools, (iii) support after hospital discharge and (iv)
Aboriginal health worker involvement in this support.
Healing Right Way is a stepped wedge trial that implements and assesses the impact of a research-informed
culturally secure [15] intervention model for Aboriginal people with brain injury in eight hospital sites
in Western Australia (WA). The trial is registered in
the Australia New Zealand Clinical Trials Registry
(ACTRN12618000139279) and has received multiple relevant ethics approvals. The main trial protocol [16] was
published previously. The current version of the trial protocol is Version 5 dated 3/11/20. This document updates
and extends the statistical analyses outlined in the protocol and describes the presentation of results for the principal paper(s) which will report the results of the primary
and secondary effectiveness hypotheses.
Study overview
Aims and hypotheses

The primary hypothesis is:

H1. Compared to usual care (UC), implementation of
the proposed intervention package (IP) will result in
a higher score on the Euro QOL–5D-3L [17] VAS at
26 weeks post-injury.
The secondary hypotheses are:
H2. Compared to UC, implementation of the IP will
result in an improvement in service delivery at 12
and 26 weeks post-injury as evidenced by increased
occasions of service.
H3. Compared to UC, implementation of the IP
will result in an improvement in service delivery at
12 and 26 weeks post-injury as related to increased
compliance with minimum process of care indicators.
H4. Compared to UC, implementation of the IP will
result in significant reduction in disability (Modified
Rankin Scale, mRS) [18] and greater independence
(Functional Independence Measure, FIM™) [19] at
12 and 26 weeks post-injury.
H5. Compared to UC, implementation of the IP will
result in significantly less carer burden (Modified
Caregiver Strain Index) [20] and less brain injury
survivor anxiety and depression (Hospital Anxiety
and Depression Scale) [21] at 12 and 26 weeks postinjury.
H6. The culturally sensitive IP will be more costeffective (additional benefits gained will justify additional costs for delivering the intervention; may lead
to potential cost-offsets from less severe disease)
than UC 26 weeks post-injury.
H7. The IP will be acceptable to health professionals
and Aboriginal participants and their families, and
the role of the Aboriginal Brain Injury Coordinator is
a feasible one.
The primary hypothesis (H1) and the first four of these
(H2–H5) will be the focus of this statistical analysis plan.
Cost effectiveness (H6) will be assessed by the health
economics expertise within the trial team and will be
published separately. Acceptability and feasibility of the
Aboriginal Brain Injury Coordinator intervention (H7)
will be assessed using qualitative analysis methods as per
the published protocol for the project’s Process Evaluation [22].
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Study design

Healing Right Way was planned as a stepped wedge trial
with four steps over 3 years. Eight sites (four rural hospitals and four urban sites) are participating in the trial.
The 3-year timeframe was divided into six 26-week periods. At the start of the trial, all sites were in the control
condition which contributed a baseline measurement for
all sites. The trial plan called for two sites cross over to
the intervention condition, at the end of the first 26-week
period, while the other sites remained in the control
condition. At the end of the second 26-week period,
two additional sites were to cross over from the control
condition to the intervention condition, and at the end
of the third 26-week period, the last two sites were to
cross over to the intervention condition. Starting with
the fifth 26-week period, all sites were to be in the intervention condition. The trial design allowed for one additional 26-week period in which all sites were to be in the
intervention condition. We recruited fewer people than
anticipated—especially in the initial periods after the
trial commenced. The trial design was therefore modified to accommodate the reduced recruitment numbers.
On advice of the Trial Management Committee, the trial
design maintained four steps as planned, but the baseline

extended period by an additional 26 weeks. The modified
design is presented in Fig. 1.
Participants were initially recruited within 4 weeks
post-injury. This was amended during Period 1 to 6 weeks
post-injury to enable recruitment of otherwise eligible
patients who were only referred to the study immediately
prior to the 4-week cut-off and for whom the recruitment
process could not be organised within the short time
frame. Outcome data were collected from participants
and caregivers at 12 weeks and 26 weeks post-injury (as
outlined in Table 1 below). Baseline assessments were
predominantly conducted at the trial site at the time of
recruitment. However, an amendment during Period 1
enabled recruitment in the community, to enable participants who were only referred to the study immediately
prior to hospital discharge to be recruited. Participants
were generally expected to have been discharged from
the hospital sites prior to the 12-week and 26-week
assessments. These assessments were therefore predominantly conducted off-site.
Randomisation of sites

Since the rural sites are smaller in size and were expected
to recruit fewer participants, a restricted randomisation
strategy was considered appropriate. Moreover, due to

Fig. 1 Implemented stepped wedge design

Table 1 Schedule for collection of participant-level outcome measures
Data collection point (time post-injury)

Baseline (0–6 weeks)

Demographic data

X

Type of injury (TBI/stroke)

X

EuroQoL-5D-3L

1 (12 weeks)

2 (26 weeks)

X

X

X

X

mRS

FIM™

X
X

X

X

HADS

X

X

X

Participant satisfaction

X

X

Modified Caregiver Strain Index (administered to participant’s
caregiver)

X

X
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differences in the availability of advanced care in the four
rural sites, patients are often transferred from these sites
to one of the urban sites. Therefore, for the purpose of
randomisation, each rural site was paired with the urban
site to which it usually transfers patients for acute care
as needed. The four pairs formed by this process were
treated as clusters for the purposes of randomisation.
These clusters were designated as A, B, C or D by the
trial data and operations manager. The trial statistician
who was blinded to this designation, then generated the
sequence in which the clusters would cross over to the
intervention condition, using simple randomisation.
Recruitment and allocation of participants

The trial used a continuous recruitment strategy [23, 24].
All eligible participants who presented to a participating
site in the trial period were invited to participate. Participants who accepted the invitation were allocated to the
trial intervention phase (control or intervention) that the
site was undergoing at the time of their recruitment.
Patient population

The patient population consisted of Aboriginal Australians, 18 years or older who presented at one of eight hospital sites in Western Australia during the trial period
after having experienced either an acute stroke or traumatic brain injury and were within 6 weeks post event.
Participants had to have a neurological deficit present as
reflected on the NIHSS [25] (stroke patients). Patients
with TBI could not have a Glasgow Coma Scale (GCS)
[26] of < 8. All had to be deemed to be able to benefit
from rehabilitation by their medical and allied health
team. Further detailed inclusion and exclusion criteria
are provided in the published study protocol [16].
The intervention

The trial implemented a complex intervention consisting of cultural security training for hospital staff and the
employment of Aboriginal Brain Injury Coordinators
(ABIC) to see the participants in hospital and up until
26 weeks post-injury onset and provide education, support, liaison and advocacy services to the participants
and their families. The cultural security training involved
workshops training 20 health professionals at each site
(nursing, medical and allied health staff ). The workshops were offered every 6 months during the intervention period for the site and consisted of a 3-h face to face
component and 3 h of online modules. The Aboriginal
Brain Injury Coordinator component required the Coordinator to be in contact with the participant a minimum
of six times following their injury on a monthly basis during the intervention period.
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Sample size

Our sample size estimation procedure involved three
steps. In the first step, we conducted a naïve sample
size estimation which ignored the clustering effects of
data collected through the stepped wedge design. In
the second step, we calculated the design effect of the
stepped wedge, using the method presented by Woertman et al. [27]. We then calculated the total sample
size required by multiplying the naïve sample size calculated in the first step by the design effect and the
total number of time periods in the planned design.
Our estimation was based on our primary outcome
measure of Euro QOL–5D [17] VAS. We did not have
any studies or preliminary data on the use of this measure in Aboriginal Australian populations. Therefore,
our estimate of the effect of the intervention was based
on the mean difference on the Euro QOL–5D [17] VAS
between stroke and non-stroke populations in the published literature. Based on the literature [28, 29], the
mean difference between stroke and non-stroke populations on the Euro QOL–5D [17] VAS was approximately 25 points with a standard deviation of 25.
Guided by this information, we assumed that the intervention would result in an improvement of 15 points
on the Euro QOL–5D [17] VAS (with a standard deviation 25), which equates to a standardised effect size of
d = 0.6 for an independent sample t-test.
Using GPower 3.1 [30], we estimated the naïve sample size for an independent samples t-test and calculated that we would require a total of 90 participants
to detect our estimated difference of d = 0.6 with 80%
power at the 5% significance level.
The design effect proposed by Woertman et al. [27]
is based on the number of clusters, number of steps,
number of measurements at the end of each step and
number of baseline measurements. Our proposed
design had four clusters which were randomised to
commence intervention in four steps, one baseline
measurement and one measurement at the end of each
step. We assumed a conservative intraclass correlation
of 0.08. Based on these inputs, we calculated a design
effect of 0.56. Multiplying the naïve sample size (n = 90)
by the design effect (DEsw = 0.56) and the number of
time periods in the trial (n = 24), and rounding-up our
results to ensure that the number of patients per cluster per time period was an integer, we obtained a total
sample size of 312 or 13 per cluster per time period.
We note that this approach may have over-estimated
the required sample size since our design:
(1) Incorporates an extra follow-up period which is not
accounted for in the estimation.
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(2) Calls for two measurements for each individual
(at each step): one at 12 weeks and the second at
26 weeks
(3) Includes a round-up error by ensuring an integer
value of participants in each cluster in each time
period.
However, since we had little or no prior information
in our estimates of effect size and intraclass correlation
coefficient, this conservative approach in our estimation
of total sample size was appropriate. Moreover, our estimate allowed for a 4% drop-out rate. Due to pragmatic
considerations including the sparse distribution of the
trial population in remote geographical regions, the estimated sample size was believed to be the maximum that
could be achieved within the trial timeframe. Therefore,
no additional allowance for drop-out was included in our
sample size estimation.
Blinding

All assessors were independent of the researchers
involved in the intervention or the trial. Since the implementation of the intervention involved providing the
treating clinicians with cultural security training, blinding of the treating clinicians was not possible. Similarly,
since the intervention required the participant and/or
the participant’s next of kin to interact with the ABIC, it
was expected that the participants would be aware if they
were receiving intervention. Therefore, the participants
are not considered to have been blinded.
Assessments

Participants were assessed at three timepoints on the
outcome measures outlined below—within 6 weeks of
injury and at 12 and 26 weeks post-injury (see Table 1).
Demographic data, injury type and severity, functional
independence measures and hospital anxiety and depression were recorded at the baseline assessment.
Primary outcome measure

The primary endpoint is the Euro QOL–5D-3L [17] VAS
at 26 weeks post-injury.
Secondary participant‑level outcome measures
Participant outcome measures

The secondary participant-level outcome measures are:
• The modified Rankin Scale (mRS) [18]
• The Functional Independence Measure (FIM) [19]
• The Hospital Anxiety and Depression Scale(HADS)
[21]
• Participant satisfaction
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In addition, the Euro QOL–5D-3L [17] VAS at
12 weeks post-injury is considered a secondary outcome
which will be reported in descriptive statistics but is not
the subject of any hypotheses.
Caregiver outcome measures

The Modified Caregiver Strain Index [20] was administered at 12 weeks and 26 weeks post-assessment.
Other participant‑level data

Demographic data collected at time of recruitment
includes:
•
•
•
•
•

Age
Gender
Recruitment site
Living arrangements prior to injury
Stroke/brain injury risk factors, e.g. hypertension,
diabetes, alcohol consumption, adverse events (AEs)
and serious adverse events (SAEs) that occurred
while a participant was enrolled in the trial were
recorded when notified.

System‑level outcome measures

The health system-related outcomes recorded in this trial
are:
• Minimum Processes of Care administered for each
participant (including, e.g. use of interpreters,
involvement of Aboriginal Liaison Officer, discharge
plan involving family)
• Occasions of service
• Resource utilisation using a purposefully designed
questionnaire completed by each participant
These data are collected according to the schedule in
Table 2 below:
Data management

Data collected during the trial will be recorded and stored
using the RedCap™ [31] electronic data capturing tool.
Additional data on outpatient use of allied health services
during the trial period will be obtained from the Western Australia Department of Health (WA DoH). Data on
Table 2 Schedule for recording of system-level outcome measures
Data collection point
(time post-injury)

Baseline
(0–6 weeks)

1 (12 weeks)

2 (26 weeks)

Process of care indicators

X

X

Occasions of service

X

X

Resource utilisation

X

X

Resource utilisation will be used for the economic evaluation [16]
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inpatient use of allied health services during the trial will
be obtained from the Allied Health System (AHS) where
possible and manual extraction from medical files when
not. In addition, data on Minimum Processes of Care will
be extracted manually from files at the participating hospital sites. These data will be stored in comma separated
values (csv) files, which will be merged with the trial data
from RedCap™ [31] during analysis. All data and scripts
generated for analysis will be archived and stored at the
lead institution (Edith Cowan University) for a period of
7 years. Access to this data will be controlled by the lead
chief investigator.

Statistical analysis plan
Analysis principles and general considerations

• All outcomes and analyses were prospectively characterised as primary or secondary.
• This is a superiority trial with intervention expected
to yield superior outcomes, compared to control.
However, all outcomes will be tested independently
at the two-tailed 5% significance level. All estimates
of treatment effects will be presented with 95% confidence intervals
• No formal adjustments will be undertaken to constrain the Type I error associated with planned secondary or exploratory analyses. The information
provided by analyses is designed to supplement the
evidence from the primary analyses; it will provide
a more complete characterisation of the treatment
effects.
• The analyses for all quantitative outcome measures
will be conducted on an intention the treat (ITT)
basis, i.e. all participants will be analysed in the trial
phase (control or intervention) in which they were
recruited, regardless of whether their treatment
adhered to the trial protocol or not. The ITT strategy
for this trial is based on the following principles:
◦ All available outcome data are collected on all
recruited participant
◦ For the ITT analysis, the outcomes for each participant will be included in the data for the trial
phase (control/intervention) in which the participant was recruited.
◦ All available outcome data will be used in the
primary analyses. The primary analyses will be
reported without imputation of missing data. If the
amount of missing data exceeds 10% at the primary
endpoint, missing data will be imputed under the
assumption that data is missing at random.
◦ A sensitivity analysis including all randomised
individuals will be conducted. The sensitivity analy-
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sis will consider alternative assumptions about data
missing not at random (MNAR).
• For primary and secondary analyses, the treatment
effects for the participant-level effectiveness outcomes will be adjusted for brain injury type (stroke
or TBI) and severity of injury (mRS) [18] at baseline.
In addition, age at recruitment, timepoint (time since
injury) and time period (6-month block of time in
which the participant is recruited to the step-wedge
trial) will be included as fixed effects. Hospital site
will be included as a random effect. Unadjusted analyses will be reported separately from these pre-specified analyses.
• All analyses will be conducted using the R Statistical
Programming Language [32] after data collection is
completed and the database is locked.
Interim analysis

No interim analyses were planned for this trial. The Data
and Safety Monitoring Committee (DSMC) reviewed
safety and effectiveness data during the course of the trial.
Due to the sequential nature of the trial (control condition precedes intervention condition at each site), there
were no formal stopping conditions for effectiveness.
The DSMC was guided by the Haybittle-Peto boundaries
[33] in assessing safety concerns. That is, they could have
recommended stopping of the trial if the number of serious adverse events (SAEs) in the intervention condition
exceeded the number of SAEs in the control condition by
at least 3 standard errors.
Trial profile

The trial will be reported in accordance with the CONSORT extension for stepped wedge cluster randomised
trials [23]. A CONSORT Flow Diagram will depict the
total number of people screened for the trial and reasons for exclusion. Numbers related to withdrawal/loss to
follow-up will be included in the diagram, with reasons
detailed in text form.
Demographics and baseline characteristics

Participant demographic and baseline clinical characteristics will be reported for participants recruited in
each condition (control or intervention). Demographic
characteristics will include age at recruitment, gender,
recruitment region (metropolitan vs regional), place
of residence (urban area, inner regional, outer regional,
remote, very remote as per the Accessibility/Remoteness
Index of Australia ARIA +) [34] and living arrangements
prior to hospital admission. Baseline clinical characteristics will include injury type, injury severity (GCS [26] for

Armstrong et al. Trials

(2022) 23:886

Page 7 of 14

TBI, NIHSS [25] for stroke and mRS [18] for all), HADS
[21], FIM [19], history of alcohol consumption and drug
use. Comorbidities/risk factors such as diabetes, renal
and heart disease will be included. Categorical variables
will be summarised using frequencies and percentages.
Unless otherwise indicated in the tables, percentages will
be based on the number of patients for whom data are
available. Continuous variables will be summarised by
the mean and standard deviation (SD) or by the median
and interquartile range (IQR). The format for presentation of this data is outlined in Table 3 of Appendix.

of care (MPC) is defined as the achievement of at least
80% of all process of indicators that are applicable to a
participant. The achievement of MPCs will be reported
as a binary variable (achieved/not achieved) at 12 and
26 weeks post-injury. Frequencies and percentages by
trial phase (control/intervention) will be reported.

Adherence to intervention protocol

Analysis of primary outcome
The primary effectiveness hypothesis states

The number and percentage of participants who received
the services of the ABIC will be reported. In addition, the
number and percentage of participants who received the
minimum number of ABIC visits (six visits on a monthly
basis) as recommended in the protocol will be reported.
In terms of the ABIC service, the per protocol groups will
be formed based on whether participants adhered to the
stated protocol or not—those who received the minimum
amount of intervention will be included in the intervention group and those who did not receive the stated
minimum amount of intervention, will be included in the
control group. All hypotheses will be re-tested using the
same models and standards as stated for the ITT analysis.
The cultural security training will be reported in terms of
a simple statement of the number of sites which received
the required training.
Outcome measures
Participant‑level outcome measures

Participant-level outcome measures were measured at
12 weeks and 26 weeks post-injury, as outlined in the
schedule in Table 1 (above). These include EuroQoL5D-3L [17], mRS [18], FIM [19], HADS [21] and the
Modified Caregiver Strain Index [20]. The mRS [18] score
will be dichotomised into independent (0–2) or dependent / dead (3–6) and reported as a binary variable. Frequencies and percentages of the mRS [18] categories
will be reported by trial phase (control/intervention).
All other outcome measures will be treated as continuous; for these measures, the mean score will be reported
together with the standard deviation.
System‑level outcome measures

The median and IQR will be reported for occasions of
service by trial phase (control/intervention).
Minimum processes of care (MPC) The trial protocol
lists twelve processes or care, not all of which are applicable to all participants (e.g. not all participants will require
an interpreter). The achievement of minimum processes

Details of how these outcomes will be presented are outlined in Table 4 (12-week outcomes) and Table 5 (26week outcomes) of Appendix.

Compared to UC, implementation of the proposed intervention package (IP) will result in a higher score on the
Euro QOL–5D-3L [17] VAS at 26 weeks post-injury.
Analysis

A mixed effects linear regression model will be used to
assess the between-group difference on Euro QOL–
5D-3L [17] VAS score at 26 weeks post-injury. The model
will control for injury type and severity (dichotomised
mRS [18] at baseline), age at recruitment and time period
(time since commencement of the trial) as fixed effects;
recruitment site and participant/individual will be
included as random effects. The treatment effect will be
reported as the mean difference between the intervention
condition and the control condition, together with the
95% confidence interval for the difference.
Treatment of missing values

The primary analysis will be reported without imputation of missing data. If the amount of missing data warrants imputation (i.e. the number of missing values on
the primary outcome measure exceeds 10%), missing
data imputation will be conducted under the assumption
that missing values are missing at random (MAR) [35].
That is, it is assumed that the values of the missing data
may reasonably be predicted from all observed data. In
particular, it will be assumed that missing values of the
primary outcome measure (Euro QOL–5D-3L [17] VAS
at 26 weeks post-injury) may be estimated from variables on which data has been collected (e.g. injury type,
baseline injury severity, baseline mRS [18], age, gender,
site, minimum processes of case, Euro QOL–5D-3L [17]
VAS at 12 weeks post-injury), and on the observed values
of Euro QOL–5D-3L [17] VAS at 26 weeks post-injury.
To ensure robustness of the imputation, 20 imputed
data sets will be generated with a separate model being
developed for each imputation. These multiple imputations will be conducted using chained Eqs. [36, 37]. The
pooled result of these imputed models will be reported
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and compared with the primary model (without imputed
data).
Sensitivity analyses

The imputation of missing values of the primary outcome
is planned under an assumption of missing at random
(MAR); therefore, a sensitivity of the results will be conducted to explore plausible departures from MAR.
The 2010 National Research Council Panel on the
Handling of Missing Data in Clinical Trials [35] recommended a transparent and easily interpretable method
for conducting a sensitivity analysis. Specifically, it recommended adding a parameter (delta) to the mean
response. The parameter, delta, measures the degree of
departure from missing at random. We propose using
this approach to conduct a sensitivity analysis that
assesses sensitivity of the results to plausible departures
from the MAR assumption in this trial. If the inference
about the treatment effects can be overturned by plausible values of the delta parameter, then the results of the
trial will be considered equivocal.
Secondary statistical hypotheses

The secondary effectiveness hypotheses (H2–H5) yield
the following statistical hypotheses:
H2.1 Compared to usual care, implementation of the
IP will result in increased occasions of service in the
first 12 weeks post-injury.
H2.2 Compared to usual care, implementation of
the IP will result in increased occasions of service
across the first 26 weeks post-injury.
H3.1 Compared to usual care, implementation of
the IP will result in an increased proportion of participants receiving at least the minimum processes
of care in the first 12 weeks post-injury.
H3.2 Compared to usual care, implementation of
the IP will result in an increased proportion of participants receiving at least the minimum processes
of care across the first 26 weeks post-injury.
H4.1 Compared to usual care, implementation of
the IP will result in an increased proportion of participants achieving independence as determined by
mRS [18] at 12 weeks post-injury.
H4.2 Compared to usual care, implementation of
the IP will result in an increased proportion of participants achieving independence as determined by
mRS [18] at 26 weeks post-injury.
H4.3 Compared to usual care, implementation of
the IP will result in increased FIM™ [19] at 12 weeks
post-injury.
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H4.4 Compared to usual care, implementation of
the IP will result in increased FIM™ [19] at 26 weeks
post-injury.
H5.1 Compared to usual care, implementation of
the IP will result in lower scores on the Modified
Caregiver Strain Index [20] at 12 weeks post-injury.
H5.2 Compared to usual care, implementation of
the IP will result in lower scores on the Modified
Caregiver Strain Index [20] at 26 weeks post-injury.
H5.3 Compared to usual care, implementation of
the IP will result in lower anxiety as measured on
the Hospital Anxiety and Depression Scale [21] at
12 weeks post-injury.
H5.4 Compared to usual care, implementation of
the IP will result in lower anxiety as measured on
the Hospital Anxiety and Depression Scale [21] at
26 weeks post-injury.
H5.5 Compared to usual care, implementation of
the IP will result in lower depression as measured on
the Hospital Anxiety and Depression Scale [21] at
12 weeks post-injury.
H5.6 Compared to usual care, implementation of
the IP will result in lower depression as measured
on the Hospital Anxiety and Depression Scale [21] at
26 weeks post-injury.

Analysis of secondary statistical hypotheses
Occasions of service

A linear mixed effects regression model will be used to
assess between-condition differences on occasions of service [H2]. Time period, age at recruitment, injury type
and severity (dichotomised mRS [18] at baseline) will be
controlled for as fixed effects in the model. Recruitment
site and participant/individual will be included as random
effects. In addition, time since injury and the interaction
of time since injury with condition (control/intervention)
will be included in the model. The interaction effect will be
used to assess the between-group differences at 12 weeks
post-injury [H2.1] and at 26 weeks post-injury [H2.2].
Processes of care

Minimum care processes [H3] will be dichotomised as
achievement of minimum care processes (at least 80%
of all applicable processes of care administered) versus
non-achievement of minimum care processes. A mixed
effects logistic regression model will be used to assess
between-condition differences on this binary variable.
Time period, age at recruitment, injury type and severity
(dichotomised mRS16 at baseline) will be controlled for
as fixed effects in the model. Recruitment site and participant/individual will be included as random effects.
In addition, time since injury and the interaction of time
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since injury with condition (control/intervention) will be
included in the model. The interaction effect will be used
to assess the between-group differences at 12 weeks postinjury [H3.1] and at 26 weeks post-injury [H3.2].
Stroke disability/injury severity

The score on the mRS [18] will be dichotomised as independent (mRS [18] 0–2) or dependent /dead (mRS [18]
3–6). A mixed effects logistic regression model will be
used to assess between-condition differences on this
binary variable. Time period, age at recruitment, injury
type and severity (dichotomised mRS [18] at baseline) will be controlled for as fixed effects in the model.
Recruitment site and participant/individual will be
included as random effects. In addition, time since injury
and the interaction of time since injury with condition
(control/intervention) will be included in the model.
The interaction effect will be used to assess the betweengroup differences at 12 weeks post-injury [H4.1] and at
26 weeks post-injury [H4.2].
Functional independence

A linear mixed effects regression model will be used to
assess between-condition differences on the Functional
Independence Measure (FIM™) [19]. Time period, age at
recruitment, injury type and severity (dichotomised mRS
[18] at baseline) will be controlled for as fixed effects in
the model. Recruitment site and participant/individual
will be included as random effects. In addition, time since
injury and the interaction of time since injury with condition (control/intervention) will be included in the model.
The interaction effect will be used to assess the betweengroup differences at 12 weeks post-injury [H4.3] and at
26 weeks post-injury [H4.4].
Caregiver strain

Data on the Modified Caregiver Strain Index [20] was
obtained from 25 next-of-kin at 12 weeks post-injury
and 21 next-of-kin at 26 weeks post-injury. Given the
relatively small sample size for these data, differences
in caregiver strain between the control and intervention phases of the trial will be assessed using independent samples t-tests. The t-tests will be conducted at the
5% significance level, and 95% confidence intervals will
be reported. No additional modelling will be undertaken
and no adjustments for any covariates will be made.
Anxiety and depression

Separate linear mixed effects regression model will be
used to assess between-condition differences on anxiety
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and depressions scales of the HADS [21]. Time period,
age at recruitment, injury type and severity (dichotomised mRS [18] at baseline) will be controlled for as
fixed effects in the models. Recruitment site and participant/individual will be included as random effects.
In addition, time since injury and the interaction of time
since injury with condition (control/intervention) will
be included in the models. The interaction effect will be
used to assess the between-group differences at 12 weeks
post-injury [H5.3] and at 26 weeks post-injury [H5.4].
Safety assessments

Adverse events (AEs) are classified as possibly, probably or
definitely attributable to the intervention. Serious adverse
events (SAEs) are classified as not related, unlikely, possibly, probably or definitely attributable to the intervention
as they occur (between consent and 26 weeks post brain
injury). AEs and SAEs will be reported by condition (control/intervention) in the main paper. The structure of this
table is presented in Table 6 of Appendix.
AEs and SAEs possibly, probably or definitely attributable to the intervention are expected to be rare.
Therefore, no formal hypotheses are associated with
these. As rare events, AEs and SAEs are expected to
have a Poisson or a negative binomial distribution. If
the data suggests that there is a between-condition difference of more than 3 standard deviations in AEs or
SAEs, the distribution will be modelled, and an appropriate generalised linear model will be developed to
assess between-condition differences.

Changes since the commencement of the trial
Recruitment rate

Recruitment remained below the anticipated rate
throughout the trial. This was due to a number of issues
including:
• The COVID-19 pandemic from 2020 to the trial
close;
• Difficulty experienced in recruitment of people
with TBI;
• A hiatus in the recruitment of participants incapable of independent consent, i.e. discontinuation
of approval to gain consent by proxy from 2018 to
2020 as part of the Western Australian Guardianship and Administration Amendment (Medical
Research) Act 2020 [38];
• Initial ethical approval for recruitment within
hospital setting only—participants were often discharged before being recruited; even after approval
was gained to recruit within the community, this
remained problematic as many were rural resi-
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dents, and recruiting remotely proved to be challenging; and
• Limited availability of recruiters in some hospitals
at times, e.g. staffing shortages.
All assessments in this trial were designed to be undertaken remotely or in person and are validated for remote
administration. Similarly, the Aboriginal Brain Injury
Coordinator services were able to be undertaken via telephone and telehealth, as planned. Therefore, COVID-19
pandemic, which was declared as a global pandemic on
March 23, 2020, did not affect the administration of the
trial for recruited participants. Recruitment concluded
on 31 July 2021, as planned. The total number of patients
recruited was 108 with uneven distribution across sites
and clusters. The numbers recruited by site/cluster per
time period are presented in Table 7 in Appendix.
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Appendix
Tables 3, 4, 5, 6 and 7

Table 3 Participant
characteristics

demographics

Intervention

All

n (%)

n (%)

Regional
Patient details
Age median (IQR)
< 65
65–80
> 80
Gender

The final sample size of 108 was approximately onethird the estimated minimum required sample size of
312. As a result, one or more of our proposed mixed
effects regression models (linear or logistic) may fail to
converge. Nevertheless, we will attempt to fit the models as proposed in the first instance. If the model for an
outcome measure fails to converge, we will approach
the modelling of that outcome by removing effects
from the model in the following order:

Female

(1)
(2)
(3)
(4)
(5)

Time period
mRS [18]
Injury severity
Injury type
Site

If the model for an outcome still fails to converge,
the outcome may be modelled with separate models
at each timepoint: 12 weeks or 26 weeks. In this case,
time since injury and interaction between time since
injury and condition (control/intervention) will be
redundant. The other effects will be included in the
model using a forward selection strategy to achieve the
best model based on the Akaike Information Criterion
(AIC). The assumptions for all statistical models will
be assessed graphically using residual plots.
Current trial status

Recruitment to Healing Right Way finished July 31, 2021,
with final follow-up of participants completed Jan 31,
2022. Data lock is anticipated to be March 18. The final
version of the statistical analysis plan was approved by all
members of the research team on March 8, 2022.

Other/not disclosed
Place of residence prior to brain injury
Urban area
Inner regional
Outer regional
Remote
Very remote
Living arrangements prior to brain injury
Home (alone)
Home (with others)
Supported accommodation,
e.g. nursing home, hostel
No fixed home
Other
Injury type
TBI
Stroke
Injury severity
Mild
Medium
Severe
Baseline mRS (binary)
Independent (0–2)
Dependent/dead (3–6)
Baseline HADS
Anxiety
Depression
Baseline FIM
Alcohol consumption
Drug use (Yes)
Diabetes (Yes)
Heart disease (Yes)

clinical

n (%)

Metropolitan

Male

baseline

Control

Recruitment region

Effect of lower sample size on statistical analysis plan

and
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Table 4 Outcomes at 12 weeks

Table 6 Adverse events and serious adverse events
Control Intervention All

Primary outcome measure
EuroQoL-5D-3L

No. of adverse events (AEs)

Secondary participant-level outcomes

Neurological complications

mRS

FIM™

0

HADS: Anxiety

2

1

HADS: Depression

>2

Participant satisfaction

No. of serious adverse events (SAEs)

Modified Caregiver Strain Index

0

System-level outcomes

1

Minimum Processes of Care Achieved
(Yes)

2
>2

Occasions of Service

Table 5 Outcomes at 26 weeks
Control Intervention All
Primary outcome measure
EuroQoL-5D-3L
Secondary participant-level outcomes
mRS

FIM™
HADS: Anxiety
HADS: Depression
Participant satisfaction
Modified Caregiver Strain Index
System-level outcomes
Minimum Processes of Care Achieved
(Yes)
Occasions of Service

Control

Intervention

All

n (%)

n (%)

n (%)
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Table 7 Actual recruitment numbers
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